Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FAS Antibody (Phospho-Tyr291) | Login | FAS Antibody (Phospho-Tyr291) | ||||||||||||||||
|
||||||||||||||||||
| SPANXB1 Protein Lysate | Login | SPANXB1 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| SPANXA2 Protein Lysate | Login | SPANXA2 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| TP53TG3B Protein Lysate | Login | TP53TG3B Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| PRAMEF14 Protein Lysate | Login | PRAMEF14 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| PRAMEF14 Protein Lysate | Login | PRAMEF14 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| RGPD6 Protein Lysate | Login | RGPD6 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| RELL1 Protein Lysate | Login | RELL1 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| SHISAL2B Protein Lysate | Login | SHISAL2B Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| SPANXB2 Protein Lysate | Login | SPANXB2 Protein Lysate | ||||||||||||||||
|
||||||||||||||||||
| TANK Antibody - middle region | Login | TANK Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| TIRAP Antibody (Phospho-Tyr86) | Login | TIRAP Antibody (Phospho-Tyr86) | ||||||||||||||||
|
||||||||||||||||||
| TIGD1 Antibody - middle region | Login | TIGD1 Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| ETV6 Antibody - C-terminal region | Login | ETV6 Antibody - C-terminal region | ||||||||||||||||
|
||||||||||||||||||
| TNFAIP8 Antibody - middle region | Login | TNFAIP8 Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| STEAP1 Antibody - N-terminal region | Login | STEAP1 Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| GTF2I Antibody (Phospho-Tyr248) | Login | GTF2I Antibody (Phospho-Tyr248) | ||||||||||||||||
|
||||||||||||||||||
| GTF3C2 Antibody - N-terminal region | Login | GTF3C2 Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| BIRC5 Antibody | Login | BIRC5 Antibody | ||||||||||||||||
|
||||||||||||||||||
| SDC4 Antibody (Phospho-Ser179) | Login | SDC4 Antibody (Phospho-Ser179) | ||||||||||||||||
|
||||||||||||||||||
| STK33 Antibody - N-terminal region | Login | STK33 Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| ZFP36L1 Antibody (Phospho-Ser92) | Login | ZFP36L1 Antibody (Phospho-Ser92) | ||||||||||||||||
|
||||||||||||||||||
| ZFP36L1 Antibody | Login | ZFP36L1 Antibody | ||||||||||||||||
|
||||||||||||||||||
| STAT5A Antibody (Phospho-Ser726/731) | Login | STAT5A Antibody (Phospho-Ser726/731) | ||||||||||||||||
|
||||||||||||||||||
| STAT6 Antibody (Phospho-Tyr641) | Login | STAT6 Antibody (Phospho-Tyr641) | ||||||||||||||||
|
||||||||||||||||||


